Evolent Health, Inc. Q3 FY2025 earnings call

• Organic Growth: Q3 revenue at top of guidance; two new revenue arrangements signed. Performance suite contract with Blue Cross plan to launch in May 2026, contributing ~$300M in 2026; provider-sponsored health plan deal adds to oncology solution. New signings add over $550M in 2026 revenue, total under contract ~$2.5B.
• Margins: Q3 adjusted EBITDA $39M, upper half of range. Enhanced protections in Performance Suite revenue for 2026, aiming for sustainable margin growth. AI review (Copilot) rolled out in musculoskeletal workflows, realizing efficiency improvements.
• Capital Allocation: Sale of Evolent Care Partners on track to close, proceeds to pay down senior term loan. No significant liabilities until end of 2029; commitment to delever using free cash flow.
• Product Development: Oncology Performance Suite growth opportunity; strategic partnership with American Oncology Network for oncology care; comprehensive cancer care navigation program showing 40%+ inpatient/utilization decrease and >90% patient satisfaction.
• Policy Environment: 2026 membership trends uncertain due to exchange, MA, and Medicaid changes. Expected 2026 adjusted EBITDA outlook uncertain, but new contracts will exit 2026 with >$750M in newly launched Performance Suite revenue.

Q3 revenue was $479.5 million, at the top of the guidance range. Full-year revenue is expected between $1.87 billion and $1.88 billion. Two new revenue arrangements were announced: a contract with a large Blue Cross plan to launch the Performance suite for oncology across over 650,000 MA and commercially fully insured members, expected to contribute ~$300 million in 2026 revenue; and a deal with a provider-sponsored health plan in the Southwest to deploy oncology condition management technology and services. New signings add over $550 million in 2026 revenue and over $750 million in annualized contract value, with total revenue under contract for 2026 at approximately $2.5 billion. Q3 adjusted EBITDA was $39 million, upper half of the expected range, representing 23% year-over-year growth.

• 2025: Revenue expected $1.87B-$1.88B, adjusted EBITDA $144M-$154M. Quarterly ranges: revenue $462M-$472M, adjusted EBITDA $30M-$40M.
• 2026: New signings take total under contract to ~$2.5B. Final revenue outlook in Feb 2026. Expected contract launches in 2026 position for strong bottom line growth in 2027.

• Membership Dynamics: Uncertainty in Medicaid, exchange, and Medicare membership changes, affecting revenue and EBITDA.
• Policy Changes: Impact of government policy changes, such as subsidy extensions or rejections, on membership and revenue.
• Trend Volatility: Variability in medical utilization trends, especially in exchanges, which can impact reserving and EBITDA.

Q: Talk about new contract wins and margin expectations A: Seth explains new contracts are under enhanced Performance Suite with prevalence/case mix adjustments and risk corridors. Mature margin expected around 10%, with new contracts contributing $75M+ at peak margins.

Q: MA enrollment and large payer customers A: John notes potential share gains by large customers could be a tailwind for tech and services suite.

Q: HIC subsidies and acuity shift A: John mentions contracts have protections for population changes, and active discussions with payers on rate adequacy for 2026.

Q: Oncology trends and EBITDA bridge A: John says oncology trend flat across year, with exchange benefits rush in cardiology. EBITDA bridge includes ECP divestiture ($10M), AI efficiencies ($20M), and Performance Suite margin maturation.

Q: Subsidies extension odds A: Seth thinks subsidy extension is likely, but complexity around timing and impact on populations makes precise prediction difficult.

Q: Oncology navigation solution and Part A offerings A: Seth says navigation solution is being rolled out, with potential to include Part A oncology spend management. Partnership with American Oncology Network supports better care and affordability.

Q: American Oncology partnership revenue and payer feedback A: Seth states partnership focuses on improving care quality and cost, with potential revenue impact as a knock-on effect, but primary focus is on quality and cost reduction.